KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inovio Pharmaceuticals (INO) EPS (Weighted Average and Diluted) (2016 - 2025)

Inovio Pharmaceuticals' EPS (Weighted Average and Diluted) history spans 14 years, with the latest figure at -$0.87 for Q3 2025.

  • For Q3 2025, EPS (Weighted Average and Diluted) rose 2.25% year-over-year to -$0.87; the TTM value through Sep 2025 reached -$2.55, up 42.95%, while the annual FY2024 figure was -$3.95, 35.14% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q3 2025 was -$0.87 at Inovio Pharmaceuticals, down from -$0.61 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.13 in Q3 2023 and bottomed at -$16.5 in Q4 2021.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$0.61 (2025), against an average of -$2.22.
  • The largest annual shift saw EPS (Weighted Average and Diluted) tumbled 14900.0% in 2021 before it soared 91.76% in 2023.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$16.5 in 2021, then increased by 20.55% to -$13.11 in 2022, then skyrocketed by 91.76% to -$1.08 in 2023, then soared by 48.15% to -$0.56 in 2024, then crashed by 55.36% to -$0.87 in 2025.
  • Per Business Quant, the three most recent readings for INO's EPS (Weighted Average and Diluted) are -$0.87 (Q3 2025), -$0.61 (Q2 2025), and -$0.51 (Q1 2025).